Diabetes: lipid-lowering therapies for primary prevention of CVD (40 years and over)

Indicator

The percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a lipid-lowering therapy (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years).

Resource impact

The previous indicator IND183 was as follows:

The percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years).

Indicator IND275 updates and replaces IND183 and expands the lipid-lowering therapies in the indicator beyond statins.

Atorvastatin 20 mg is recommended as first-line therapy for the primary prevention of cardiovascular disease in adults with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty. Alternative lipid-lowering therapies may be considered if statins are contraindicated or not tolerated.

This indicator therefore widens the lipid-lowering therapies in the indicator and is not expected to lead to a significant change in clinical practice. Any associated resource impact is therefore unlikely to be significant.